These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 11434364)

  • 1. Deterioration in renal function associated with fibrate therapy.
    Goffin E; Devuyst O; Pirson Y
    Clin Nephrol; 2001 Jun; 55(6):490. PubMed ID: 11434364
    [No Abstract]   [Full Text] [Related]  

  • 2. Creatininemia during fibrate therapy: a reply to Lipscombe et al.
    Hottelart C; Achard JM; Fournier A
    Clin Nephrol; 2001 Jul; 56(1):85-6. PubMed ID: 11499666
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug treatment of lipid disorders.
    Broeders N; Knoop C; Abramowicz D
    N Engl J Med; 1999 Dec; 341(26):2020-1. PubMed ID: 10617402
    [No Abstract]   [Full Text] [Related]  

  • 4. [Fibrate-induced deterioration of renal function].
    Polanco N; Hernández E; González E; Gutiérrez Martínez E; Bello I; Gutiérrez-Millet V; García F; Morales E; Praga M
    Nefrologia; 2009; 29(3):208-13. PubMed ID: 19554053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety considerations with fibrate therapy.
    Davidson MH; Armani A; McKenney JM; Jacobson TA
    Am J Cardiol; 2007 Mar; 99(6A):3C-18C. PubMed ID: 17368275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible mechanisms of the fibrate-induced increase in serum creatinine.
    Tsimihodimos V; Miltiadous G; Bairaktari E; Elisaf M
    Clin Nephrol; 2002 May; 57(5):407-8. PubMed ID: 12036205
    [No Abstract]   [Full Text] [Related]  

  • 7. Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy.
    Layne RD; Sehbai AS; Stark LJ
    Ann Pharmacother; 2004 Feb; 38(2):232-4. PubMed ID: 14742756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
    McClure DL; Valuck RJ; Glanz M; Murphy JR; Hokanson JE
    J Clin Epidemiol; 2007 Aug; 60(8):812-8. PubMed ID: 17606177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The current situation of therapy in hyperlipemias].
    Vallina Alvarez E; Arribas Castrillo JM; Suárez García E
    An Med Interna; 1990 Jul; 7(7):370-4. PubMed ID: 2103252
    [No Abstract]   [Full Text] [Related]  

  • 10. [How sure is the combined lipid lowering?].
    Schäfer J
    MMW Fortschr Med; 2005 Jan; 147(1-2):56. PubMed ID: 15704576
    [No Abstract]   [Full Text] [Related]  

  • 11. Drugs for lipid disorders.
    Treat Guidel Med Lett; 2003 Aug; 1(12):77-82. PubMed ID: 15529095
    [No Abstract]   [Full Text] [Related]  

  • 12. [Why does adequate tolerance of a lipid-lowering agent play such an important role?].
    Mutschler E
    Fortschr Med; 1990; 108 Spec No 1():54-5. PubMed ID: 2245962
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipid-lowering drugs and changes to diet can make a difference.
    TreatmentUpdate; 2001 Aug; 13(4):7-9. PubMed ID: 11590981
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
    Dupuy AM; Carrière I; Scali J; Cristol JP; Ritchie K; Dartigues JF; Gambert P; Ancelin ML
    Climacteric; 2008 Feb; 11(1):74-83. PubMed ID: 18202967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statines for all or individualized lipid lowering therapy?].
    Parhofer K
    MMW Fortschr Med; 2009 Apr; 151(14):100, 102-4; quiz 105. PubMed ID: 19504849
    [No Abstract]   [Full Text] [Related]  

  • 16. Fenofibrate can increase serum creatinine levels in renal insufficiency.
    Paul S; Mohan V
    J Assoc Physicians India; 2006 Apr; 54():337. PubMed ID: 16944623
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of metronidazole on hyperlipidaemia.
    Talwar S; Mathur AK; Prasad P
    Int J Cardiol; 2005 May; 101(1):139. PubMed ID: 15860397
    [No Abstract]   [Full Text] [Related]  

  • 18. Common obstacles in lipid management.
    Elpers M
    Crit Care Nurs Clin North Am; 2008 Sep; 20(3):287-95. PubMed ID: 18644511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing drug usage and adverse effects. Part III: Cardiovascular disease and hyperlipidemia.
    Baron M
    Health Care Food Nutr Focus; 2005 Jun; 22(6):7-11. PubMed ID: 15923907
    [No Abstract]   [Full Text] [Related]  

  • 20. Statins and polyneuropathy: setting the record straight.
    Leis AA; Stokic DS; Olivier J
    Muscle Nerve; 2005 Oct; 32(4):428-30. PubMed ID: 16094656
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.